B+
Bull case
25%
Probability
Target price
$48.00
Analysis reference price unavailable
Analysis 2026-08-14 · RankAlpha Sentiment Codex
MLYS
Mineralys TherapeuticsCNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
Quote time unavailable
Current thesis
Successful lorundrostat approval could unlock a substantial re-rating, supported by the company-reported five-trial clinical package, commercial preparation, stronger financing position, and runway into 2028 [#SEC-8K-2026-05-06] [#SEC-8K-2026-08-11].
Posture
Mixed
Lead driver
Sentiment
What changed
3 setup hits (3d) with net bullish as of 2026-09-09.
What can break
Commercial launch timing, reimbursement, market access, prescribing uptake, and execution remain uncertain.
Momentum
24
Value
41
Sentiment
67
Setup hits (3d)
3 · Net Bullish
AI TargetsBase $30.00 · Bull $48.00 · Bear $17.00Analysis 2026-08-14; returns require an exact persisted reference.
Data freshness
Prices
Unavailable: Price unavailable
Fundamentals
As of 2026-08-17 • Vendor: Data Vendor v1
Scores
As of 2026-09-09 • Model: HYBRID_IC_RP
AI Memo
As of 2026-08-14 • Model: RankAlpha Sentiment Codex
Investment thesisAs of 2026-09-09
Investment thesis
As of 2026-09-09
Grade is the composite factor band; factor scores use a 0–100 scale. Confidence describes evidence quality, not a probability of return. Score date: 2026-09-09. Definitions
Supporting evidence
What
Grade C · Mixed
Confidence Medium · Net Bullish
Target $48.50
Why
Momentum24 · Δ7d +12.6
Value41 · Δ7d 0.0
Sentiment67 · Δ7d -20.0
So what
Balanced signals (Net Bullish). Wait for confirmation before sizing up.
Confirming evidence
- • 3 setup hits (3d) with net bullish as of 2026-09-09.
- • Sentiment remains the lead driver in the composite, 7D delta -20.0.
Contradictions & invalidation
- • Commercial launch timing, reimbursement, market access, prescribing uptake, and execution remain uncertain.
- • FDA approval is not assured despite the December 22, 2026 PDUFA target.
- • The thesis remains concentrated in a single late-stage asset and a binary regulatory outcome.
Catalyst clock
2026-08-11
Q2 release: financing and commercial-readiness update
Lead driver: Sentiment · See AI snapshot
Momentum
24
9% active weight
Current posture
7d trendImproving
Δ7d
+12.6
Δ21d
+0.9
Value
41
28% active weight
Current posture
7d trendFlat
Δ7d
0.0
Δ21d
+0.1
Sentiment
67
62% active weight
Current posture
7d trendSoftening
Δ7d
-20.0
Δ21d
-19.8
Why this grade
Composite grade C. Momentum 24.1 / Value 41.2 / Sentiment 66.6
Scenario snapshot
Scenario probability is memo-authored likelihood, not forecast certainty. Targets belong to the analysis dated 2026-08-14. Scenario method
Most likely
B
Base case
50%
Probability
Target price
$30.00
Analysis reference price unavailable
Analysis 2026-08-14 · RankAlpha Sentiment Codex
B-
Bear case
25%
Probability
Target price
$17.00
Analysis reference price unavailable
Analysis 2026-08-14 · RankAlpha Sentiment Codex
Fundamentals (TTM)As of 2026-08-17
Fundamentals (TTM)
As of 2026-08-17
Market Cap
$2.3B
Beta
-
Shares Out
88.41M
P/E (TTM) · Derived
-11.4
P/S (TTM)
-
P/FCF (TTM) · Derived
-14.97
Rev YoY
-
EPS YoY
+330.3%
Gross Margin
-
Op Margin
-
Net Debt
-$656.64M
Current Ratio
34.46
As of 2026-09-09 • Updated nightlySource: Internal modelMethods & Data